Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's 10% dip reveals an opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and ...

Deep 6’s platform strengthens Tempus AI’s provider connectivity, now totaling over 4,000 connections, and facilitates the two-way exchange of clinical and molecular data.

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

Attorneys for plaintiff Trevor Shouse, who has owned Tempus stock, are seeking class-action status for all persons and entities that purchased Tempus common stock between Aug. 6, 2024, and May 27 ...

The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a ...

On June 1, Tempus AI Inc. (NASDAQ:TEM) announced the expansion of its GenAI clinical assistant, called Tempus One, with direct integration into electronic health record/EHR systems. This ...